2024-517377-24-00招募中1 期
Cardiac safety of treosulfan chemotherapy prior to stem cell transplantation in patients with leukemia.
Medac Gesellschaft fuer klinische Spezialpraeparate mbH4 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年10月18日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Trial Information
Scientific
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
TREOSULFAN LEVELS IN CHILDREN UNDERGOING STEM CELL TRANSPLANTATIOAny paediatric disease with an indication to an allogeneic stem cell transplantation (inclusing leukaemia, primary immunodeficiencies, metabolic disorders and autoimmune or genetic inflammatory bowel disorders).EUCTR2013-003257-20-GBGREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST90
进行中（未招募）
1 期
Conditioning treatment with treosulfan or busulfan for chemotherapy prior to stem cell transplantation in patients with leukemia.EUCTR2008-002356-18-DEmedac Gesellschaft für klinische Spezialpräparate mbH960
进行中（未招募）
1 期
Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens - Clinical Phase III Treosulfan based conditioning vs RICPatients with acute myeloid leukaemia (AML)or myelodysplastic syndrome (MDS) considered ineligible to standard conditioning therapies prior to allogenic stem cell transplantationMedDRA version: 9.1Level: LLTClassification code 10000881Term: Acute myeloid leukaemia (in remission)MedDRA version: 9.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSEUCTR2008-002356-18-ITMEDAC RESEARCH545
进行中（未招募）
1 期
Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens. - Clinical phase III trial of Treosulfan-based conditioning vs. RICPatients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) considered ineligible to standard conditioning therapies prior to allogeneic stem cell transplantation.MedDRA version: 9.1Level: LLTClassification code 10000881Term: Acute myeloid leukaemia (in remission)MedDRA version: 9.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSEUCTR2008-002356-18-FRmedac Gesellschaft für klinische Spezialpräparate mbH545
进行中（未招募）
1 期
Conditioning treatment with treosulfan or busulfan for chemotherapy prior to stem cell transplantation in patients with leukemia.EUCTR2008-002356-18-PLmedac Gesellschaft für klinische Spezialpräparate mbH960